# Genotype and Clinical Characteristics of Patients with Wolfram Syndrome and WFS1-related Disorders

- 1 Evan M. Lee<sup>1,3</sup>, Megha Verma<sup>1,6</sup>, Nila Palaniappan<sup>1,7</sup>, Emiko M. Pope<sup>1,8</sup>, Sammie Lee<sup>1,9</sup>,
- 2 Lindsey Blacher<sup>1</sup>, Pooja Neerumalla<sup>1</sup>, William An<sup>1</sup>, Toko Campbell<sup>1</sup>, Cris Brown<sup>1</sup>, Stacy
- 3 Hurst<sup>1</sup>, Bess Marshall<sup>4</sup>, Tamara Hershey<sup>5</sup>, Virginia Nunes<sup>10, 11s</sup>, Miguel López de Heredia<sup>12</sup>,
- 4 and Fumihiko Urano<sup>1,2</sup>
- <sup>1</sup>Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research, Washington
   University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA
- <sup>2</sup>Department of Pathology and Immunology, Washington University School of Medicine, 660 South
   Euclid Avenue, St. Louis, MO 63110, USA
- <sup>3</sup>Medical Scientist Training Program, Washington University School of Medicine, St. Louis, MO
   63110, USA
- <sup>4</sup>Department of Pediatrics, Washington University School of Medicine, 660 South Euclid Avenue, St.
- 12 Louis, MO 63110, USA
- 13 <sup>5</sup>Departments of Psychiatry and Radiology, Washington University School of Medicine, 660 South
- 14 Euclid Avenue, St. Louis, MO 63110, USA
- 15 <sup>6</sup>Saint Louis University School of Medicine, Saint Louis, MO, USA
- 16 <sup>7</sup>University of Missouri Kansas City, Kansas City, MO, USA
- 17 <sup>8</sup>Massachusetts Institute of Technology, Cambridge, MA, USA
- 18 <sup>9</sup>Cornell University, Ithaca, NY, USA
- <sup>10</sup>Molecular Genetics Laboratory. Genes, Disease and Therapy Program IDIBELL, l'Hospitalet de
- 20 Llobregat, Barcelona, Spain
- 21 <sup>11</sup>Genetics Unit. Physiological Sciences Department. Health Sciences and Medicine Faculty.
- 22 University of Barcelona, l'Hospitalet de Llobregat, Barcelona, Spain
- <sup>23</sup><sup>12</sup>Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos
- 24 III, Madrid, Spain
- 25
- 26 \* Correspondence:
- 27 Fumihiko Urano, MD, PhD
- 28 urano@wustl.edu
- 29 Keywords: Wolfram syndrome, WFS1-related disorders, diabetes mellitus, optic atrophy,
- 30 hearing loss, diabetes insipidus.
- 31

#### 32 Abstract

33	Objective: Wolfram syndrome (WFS) is an autosomal recessive disorder associated with juvenile-
34	onset diabetes mellitus, optic atrophy, diabetes insipidus, and sensorineural hearing loss. We sought
35	to elucidate the relationship between genotypic and phenotypic presentations of Wolfram syndrome
36	which would assist clinicians in classifying the severity and prognosis of Wolfram syndrome more
37	accurately.
38	Approach: Patient data from the Washington University International Registry and Clinical Study for
39	Wolfram Syndrome and patient case reports were analyzed to select for patients with two recessive
40	mutations in the WFS1 gene. Mutations were classified as being either nonsense/frameshift variants
41	or missense/in-frame insertion/deletion variants and statistical analysis was performed using unpaired
42	and paired t-tests and one- and two-way ANOVA with Tukey's or Dunnett's tests.
43	Results: A greater number of genotype variants correlated with earlier onset and a more severe
44	presentation of Wolfram syndrome. Secondly, non-sense and frameshift variants had more severe
45	phenotypic presentations than missense variants, as evidenced by optic atrophy emerging
46	significantly earlier in patients with 2 nonsense/frameshift alleles compared with 0 missense
47	transmembrane variants. In addition, the number of transmembrane in-frame variants demonstrated a
48	statistically significant dose-effect on age of onset of diabetes mellitus and optic atrophy.
49	Summary / Conclusions: The results contribute to our current understanding of the genotype-
50	phenotype relationship of Wolfram syndrome, suggesting that alterations in coding sequences result
51	in significant changes in the presentation and severity of Wolfram. The impact of these findings is
52	significant, as the results will aid clinicians in predicting more accurate prognoses and pave the way

53 for personalized treatments for Wolfram syndrome.

#### 55 1 Introduction

56 Wolfram syndrome (WFS) is an autosomal recessive disorder associated with juvenile-onset diabetes 57 mellitus, optic atrophy, diabetes insipidus, and sensorineural hearing loss [1]. Diagnosis of Wolfram 58 syndrome is usually ascertained due to the occurrence of early onset type 1 diabetes mellitus with 59 optic atrophy, which occur in the first decade of life [1; 2]. Additionally, central diabetes insipidus 60 and sensorineural deafness occur in the second decade, dilated renal outflow tracts occur in the third 61 decade, and neurological symptoms appear in the fourth decade [1]. Patients can also develop a wide 62 range of symptoms including, bladder and bowel dysfunction, temperature regulation defects, gait 63 ataxia, balance deficits, and loss of sense of taste and smell [1; 3; 4]. WFS symptoms have a 64 detrimental impact on patients' quality of life and daily functioning [3; 4]. The life span of patients is 65 expected to be around 30–40 years of age due to respiratory failure caused by brainstem atrophy [1; 66 2]. The prevalence of the disorder is estimated to be present in 1 in 100,000 in North America and 1 67 in 770,000 in the UK [1; 5].

Two causative genes, WFS1 and CISD genes have been implicated in the development of Wolfram 68 69 syndrome. WFS1 encodes for wolframin, an endoplasmic reticulum (ER) membrane glycoprotein, 70 which plays a role in Ca2+ homeostasis and regulates the ER stress response [6]. Mutations in 71 wolframin lead to ER and mitochondrial dysfunction which cause apoptosis and cell death [3]. CISD 72 encodes for an ER intermembrane small protein (ERIS) which plays a role in Ca2+ homeostasis and 73 mitochondrial function [3; 7]. Mutations in CISD were initially described in Jordanian patients with 74 unique phenotypic presentations such as bleeding tendency, defective platelet aggregation with 75 collagen, and peptic ulcer disease [8].

Additionally, pathogenic variants in *WFS1* can cause the development of *WFS1*-related disorders
involving sensorineural low frequency hearing loss, hearing loss and optic atrophy, cataracts, and an

autosomal dominant syndrome characterized by neonatal diabetes, congenital cataracts, sensorineural
deafness, hypotonia, intellectual disability, and development delay [9]. Dominant WFS1 variants
potentiate ER stress and result in pathophysiology that is distinct and less severe than patients with
recessive Wolfram syndrome [9].

82 The autosomal recessive syndrome has been characterized widely in literature and a variety of 83 pathogenic variants and polymorphisms have been reported to date. In the WFS1 variants present in 84 the literature, alterations in coding sequences have identified changes including deletions, insertions, 85 nonsense and missense mutations [10]. Associations between genotype and phenotype characteristics can suggest the role that gene alterations play in the variability of clinical phenotypes. We sought to 86 87 elucidate the relationship between genotypic and phenotypic presentations of Wolfram syndrome. 88 Additional information about genotype and phenotype correlations would allow clinicians to classify 89 the severity of Wolfram syndrome more accurately. This could aid in predicting more accurate 90 prognoses and pave the way for personalized treatments for Wolfram syndrome.

The advantages to discovering genotype and phenotype correlations are highlighted in the case of another autosomal recessive disorder, cystic fibrosis. Typing the genotype-phenotype relationship for cystic fibrosis is important as pathogenic variants can alter the expression and function of CFTR via multiple mechanisms [11; 12; 13]. Additionally, the diverse clinical consequences of cystic fibrosis can be attributed to modifier genes and the environment in combination with pathogenic variants [11; 14; 15]. As such, accurate classification of *CFTR* variants, as well as causative Wolfram variants, is essential in optimizing the treatment of individuals [11].

In this study, we aim to classify the range of severity of clinical presentations of autosomal recessive
Wolfram syndrome. We classify genetic variants by age of onset, type of genetic variant, and
location of variant to identify associations with disease severity. Due to the rare prevalence of

- 101 Wolfram syndrome, there is fragmented data regarding the correlation between genotype and
- 102 phenotype presentations. To address this, we compiled patient data from the Washington University
- 103 International Wolfram Syndrome and WFS1 Related Disorders Registry and patient data from
- 104 published case reports compiled in a systematic review by Heredia et al [2]. We performed meta-
- analysis on these data and found significant correlations between pathogenic variant characteristics
- 106 and disease severity.
- 107

#### 108 2 Materials and Methods

#### 109 2.1 Patients

110 Subjects, and their parents or legal guardians, as appropriate, provided written, informed consent

- 111 before participating in this study, which was approved by the Human Research Protection Office at
- 112 Washington University School of Medicine in St. Louis, MO (IRB ID #201107067).

113 Patient data from the Washington University International Registry and Clinical Study for Wolfram

114 Syndrome and patient case reports highlighted in Heredia et al were analyzed to select for patients

115 with two recessive variants in the *WFS1* gene [2]. Patients were excluded if they lacked genetic

116 information for either of their WFS1 allele variants. Additionally, records were excluded if they did

117 not have a numerical age of onset for their respective clinical phenotype (diabetes insipidus, optic

118 atrophy, diabetes insipidus, hearing loss). Pathogenic variants were then classified as being either

119 nonsense/frameshift variants or missense/in-frame insertion and deletion variants. The average age of

120 onset was calculated for each clinical phenotype based on the number of nonsense/frameshift alleles.

121 For patients with either 0 or 1 nonsense/frameshift variant, their other variant was classified as

122 transmembrane or not based on whether the amino acid position was in one of the transmembrane

123 domains provided on UniProt, and age of onset was noted.

#### 124 2.2 Statistical Analysis

125 Statistical analysis was performed by unpaired and paired t tests and one- and two-way ANOVA with

126 Tukey's or Dunnett's tests. Statistical tests are specified in figure legends. Error bars on all graphs

127 represent a 95% CI. P < 0.05 was considered statistically significant. Data are shown as means  $\pm$ 

128 SEM unless otherwise noted.

#### 130 **3** Results

#### 131 **3.1 Onset Age of Clinical Manifestations of Wolfram Syndrome**

- 132 Average age of onset of clinical manifestations for the combined patient cohort was calculated for
- each of diabetes mellitus, optic atrophy, diabetes insipidus, and hearing loss (Figure 1). The mean
- 134 age of onset was 7.5 years (95% Confidence Interval 6.8-8.1 years) for diabetes mellitus, followed by
- 135 12.9 years (12.0-13.8 years) for optic atrophy, 14.1 years (12.9-15.3 years) for diabetes insipidus, and
- 136 15.3 years (14.0-16.5 years) for hearing loss. The ages of onset are similar to but slightly lower than
- 137 those in a similar cohort study of 67 Japanese patients with Wolfram Syndrome, which found median
- age of onsets to be 8.7 years, 15.8 years, 17.2 years, and 16.4 years for diabetes mellitus, optic
- 139 atrophy, diabetes insipidus, and hearing loss respectively [25].

# 140 3.2 Nonsense/Frameshift *WFS1* Alleles Exhibit a Dose-Dependent Response on Disease 141 Severity

142 For each clinical manifestation of Wolfram Syndrome, patients who had information on both alleles 143 as well as numerical age of onset data were further classified based on whether they had zero, one, or 144 two nonsense/frameshift (NSFS) variant alleles. While diabetes insipidus and hearing loss showed no 145 association of onset age with the number of NSFS variants, both diabetes mellitus and optic atrophy demonstrated a dose-effect of number of NSFS variants with respect to age of onset (Figure 2A). 146 147 Both diabetes mellitus and optic atrophy emerged earliest in patients with 2 NSFS alleles, followed 148 by patients with 1 NSFS allele, followed by patients with 0 NSFS alleles and only in-frame variants. 149 Diabetes mellitus emerged significantly earlier in patients with 2 NSFS alleles compared with both 0 150 and 1 NSFS alleles, and correspondingly emerged at a mean age of 5.3 years, 7.7 years, and 9.8 years 151 for 2, 1, and 0 NSFS alleles. Optic atrophy emerged significantly earlier in patients with 2 NSFS 152 alleles compared with both 0 and 1 NSFS alleles, and correspondingly emerged at a mean age of 10.6

153 years, 13.7 years, and 15.1 years for 2, 1, and 0 NSFS alleles. One outlier to this finding is 154 emphasized in an exceptional case of typical wolfram syndrome. This patient has a phenotypical 155 clinical diagnosis of typical Wolfram Syndrome with the development of diabetes mellitus at age 5 156 and optic atrophy at age 8. However, we could only detect a frameshift pathogenic variant in one 157 allele with a corresponding normal allele. Since we could not detect two pathogenic variant alleles, 158 we hypothesized the normal allele was not expressed. This prompted us to look at the expression 159 levels of wild-type and mutated alleles by next-generation sequencing using RNA extracted from 160 induced pluripotent stem cells (iPSC) derived from this patient. Results showed no expression of the 161 wild-type allele, suggesting that there is suppression or methylation in the gene regulatory region of 162 the normal allele. There was not a statistically significant difference in the age of onset between 163 patients with 0 NSFS alleles and 1 NSFS allele for either diabetes mellitus or optic atrophy. The 164 mean onset, confidence intervals, number of patients in each category, and multiple-test-corrected q-165 values are shown in Table 1. 166 No statistically significant differences were observed in age of onset between male and female

patients, either within the above number of NSFS variant categories or for the cohort overall (Figure2B).

169 3.3 Missense WFS1 Variants in Transmembrane Domains Are Associated with Earlier Onset
 170 of Disease

171 For missense and in-frame insertion and deletion variants, amino acid position information was

172 matched against the predicted transmembrane domain annotations from UniProt. These variants were

- 173 then clarified as transmembrane (TM) or non-transmembrane (NTM). For each clinical
- 174 manifestation, the subset of patients previously defined with a) 0 NSFS alleles and consequently two
- 175 in-frame variants and b) 1 NSFS allele and 1 in-frame variant were then further classified by whether

176	their in-frame variant was TM or NTM. Average age of onset for each clinical manifestation was
177	compared by the number of TM alleles (Figure 3A). Patients with two in-frame variants (0 NSFS
178	variants) showed a similar effect of the number of transmembrane variants as seen with the number
179	of NSFS alleles, with the number of in-frame variants which were transmembrane demonstrating a
180	statistically significant dose-effect on age of onset of DM and OA. Diabetes mellitus emerged
181	significantly earlier in patients with 2 TM variants in 2 missense/in-frame variants compared with
182	both 0 and 1 NSFS variants, and correspondingly emerged at a mean age of 6.3 years, 9.0 years, and
183	13.5 years for 2, 1, and 0 TM variants. Optic atrophy emerged significantly earlier in patients with 2
184	NSFS alleles compared with patients that had 2 missense/in-frame variants with 0 TM variants.
185	There was no statistically significant difference in the age of onset between patients with 2 NSFS
186	alleles and 1 TM variant for optic atrophy. Optic atrophy correspondingly emerged at a mean age of
187	10.7 years, 14.4 years, and 19.3 years for 2, 1, and 0 NSFS alleles. The mean onset, confidence
188	intervals, number of patients in each category, and p values are shown in Table 2.
189	In patients with one in-frame variant and one nonsense/frameshift variant, an in-frame variant in a
190	TM position had statistically significant earlier onset of diabetes mellitus but none of the other
191	clinical manifestations (Figure 3B).

#### 193 4 Discussion

194	In the setting of Wolfram syndrome, we sought to explore the associations between genotype and
195	phenotype characteristics to speculate the role that gene alterations can play in the variability of
196	clinical phenotypes. It was found that both diabetes mellitus and optic atrophy demonstrated a dose-
197	effect of number of NSFS variants with respect to age of onset. In addition, the number of
198	transmembrane in-frame variants demonstrated a statistically significant dose-effect on age of onset
199	of DM and OA.

201 relationship in Wolfram syndrome. Firstly, it is suggested that a greater number of variants correlates 202 with earlier onset and a more severe presentation of Wolfram. The relationship between variant 203 characteristics and disease severity has been explored previously with the discovery of the

These results highlight principles that are important in understanding the genotype-phenotype

204 Arg558Cys mutation in Ashkenazi Jew individuals which is associated with a milder, late-onset

205 phenotype of Wolfram syndrome including early onset diabetes and reduced penetrance for optic

atrophy [16; 17].

200

Secondly, it is suggested that non-sense and frameshift mutations have more severe phenotypic presentations than missense mutations, as evidenced by optic atrophy emerging significantly earlier in patients with 2 NSFS alleles compared with 0 missense TM variants. A similar phenomenon is highlighted in the case of another autosomal recessive disorder, cystic fibrosis. Literature on genotype-phenotype correlations in cystic fibrosis predicts milder phenotypes and better prognosis associated with A455E, a missense mutation, compared to  $\Delta$ F508, a deletion mutation [18].

Additionally, it is suggested that if missense mutations are present in the transmembrane domain, there is predicted to be an earlier age of onset for the traits of DM and OA. Possible explanations for this include missense mutations in the TM domain making protein misfolding and aggregation more

216 likely. Pelizaeus-Merzbacher disease is an early-onset leukodystrophy caused by frameshift and 217 missense mutations of the PLP1 gene. Mutations can lead to protein misfolding and retention of PLP 218 and DM20 (proteins in the TM domain) in the ER, supporting the conjecture that Wolfram mutations 219 in the TM domain contribute to protein misfolding and aggregation [19]. 220 Lastly, there are no differences observed in the age of onset of DM and OA between male and female 221 patients. This finding is surprising as the pathophysiology of Wolfram syndrome involves ER stress 222 and estrogen has been shown to mitigate ER stress [20]. Additionally, in WFS1 knockout mice, males 223 have been shown to present with more severe phenotypes than females [21]. These findings raise the 224 possibility that female patients would present with milder manifestations of Wolfram syndrome; 225 however, this hypothesis was not supported by our data. 226 The impact of these findings is significant as the results offer contribution to our current 227 understanding of the genotype-phenotype relationship of Wolfram syndrome. These results highlight 228 that alterations in coding sequences result in significant changes in the presentation and severity of 229 Wolfram. 230 A possible direction to explore these findings would be to study the relationship between variants and 231 Wolfram United Rating Scale (WURS) disease severity scores [22]. Additionally, integrating these

results into the current understanding of Wolfram could allow clinicians to explore the possibility of

233 individualized treatments for Wolfram. The implications of this would include improved clinical care

for Wolfram patients, with the possibility of missense variants warranting different treatment

approaches than frameshift or non-sense variants. It would also allow patients and parents to plan for

- 236 future outcomes of the disease. Research studies exploring the expressivity of different Wolfram
- 237 causing gene variants should be undertaken. Due to Wolfram syndrome being caused by numerous

- different combinations of variants, it has been challenging to aggregate data to determine patterns inexpressivity.
- 240 Additional directions for research include exploring the correlation between levels of biomarkers and
- 241 severity of disease. Biomarkers for neurodegeneration, such as neurofilament light chain and myelin
- basic protein, and inflammatory cytokine levels have been shown to be elevated in patients with
- 243 Wolfram [23; 24]. The use of functional assays could be helpful in this regard to further explore the
- role of these biomarkers in the pathogenesis of Wolfram. Establishing a correlation between
- biomarker levels and phenotype severity will aid in the prediction of clinical outcomes and disease
- 246 progression in patients with Wolfram syndrome [23].
- 247 Although correlations between genotype and phenotype presentations for Wolfram syndrome have
- 248 been posed in this paper, further research is needed to confirm these conjectures.

# 250 Figure Legends

- 251 Figure 1. Mean age of onset of clinical manifestations of Wolfram Syndrome. Diabetes
- 252 mellitus, optic atrophy, diabetes insipidus, and hearing loss emerged respectively at mean 253 ages of 7.5, 12.9, 14.1, and 15.3 years.
- 254

# 255 Figure 2. Analysis of genotype-phenotype correlations for number of

- 256 nonsense/frameshift variants. Age of onset of different clinical manifestations by
- 257 number of nonsense/frameshift variants vs in-frame missense or insertion/deletion
- variants for the entire dataset (A) and split by patient sex (B). NSFS2: two
- 259 nonsense/frameshift variants (n=65-129). NSFS1: one nonsense/frameshift variant (n=39-
- 260 87). IF: no nonsense/frameshift variants (n=47-111). \*, P<0.05; \*\*, P<0.01; \*\*\*,
- 261 P<0.001; n.s., no significance. P-values were assigned using Wilcoxon's Rank Sum Test
- with multiple test correction applied via the Bonferroni method.
- 263

# **Figure 3. Analysis of genotype-phenotype correlations for in-frame variants by**

- 265 transmembrane/non-transmembrane domain. Age of onset of different clinical
- 266 manifestations by number of in-frame variants (either missense or in-frame
- 267 insertion/deletion) in transmembrane domains for patients with two in-frame variants (A)
- and patients with one in-frame variant (B). 2TM: Two transmembrane variants (n=24-42).
- 269 1TM: One transmembrane variant (n=7-24). NTM: No transmembrane variants (n=16-
- 45). \*, *P*<0.05; \*\*, *P*<0.01; n.s., no significance. P-values were assigned using
- 271 Wilcoxon's Rank Sum Test with multiple test correction applied via the Bonferroni
- 272 method.
- 273

#### 274 **Conflict of Interest**

- FU is an inventor of three patents related to the treatment of Wolfram syndrome, US 9,891,231
- 276 SOLUBLE MANF IN PANCREATIC BETA CELL DISORDERS and US 10,441,574 and US
- 277 10,695,324 TREATMENT FOR WOLFRAM SYNDROME AND OTHER ER STRESS
- 278 DISORDERS. FU is a Founder and President of CURE4WOLFRAM, INC. JRM is a consultant for
- 279 Sana Biotechnology.

#### 280 Author Contributions

- EL, MLDH, and FU conceived the experimental design. NP, EP, SL, LB, PN, WA, CB, SH, MV,
- 282 VN, MLDH, and FU collected information from patients and databases. EL performed data analysis.
- 283 MV, EL, and FU wrote the manuscript. All authors edited and reviewed the manuscript.

# 284 Funding

- 285 This work was partly supported by the grants from the National Institutes of Health (NIH)/NIDDK
- 286 (DK112921, DK020579, DK132090), NIH/ National Center for Advancing Translational Sciences
- 287 (NCATS) (TR002065, TR000448), and philanthropic supports from the Silberman Fund, the Ellie
- 288 White Foundation for the Rare Genetic Disorders, the Snow Foundation, the Unravel Wolfram
- 289 Syndrome Fund, the Stowe Fund, the Eye Hope Foundation, the Feiock Fund, Associazione Gentian
- 290 Sindrome di Wolfram Italia, Alianza de Familias Afectadas por el Sindrome Wolfram Spain,
- Wolfram syndrome UK, and Association Syndrome de Wolfram France to F. Urano. Research
- reported in this publication was also supported, in part, by the Washington University Institute of
- 293 Clinical and Translational Sciences grant UL1TR002345 from the NIH/NCATS. The content is
- solely the responsibility of the authors and does not necessarily represent the official view of the
- NIH. We thank all the members of the Washington University Wolfram Syndrome Study and
   Research Clinic for their support (https://wolframsyndrome.wustl.edu) and all the participants in the
- Wolfram syndrome International Registry and Clinical Study, Research Clinic, and Clinical Trials for
- 298 their time and efforts.

# 299 Acknowledgments

- 300 We thank all the members of the Washington University Wolfram Syndrome Study and Research
- 301 Clinic for their support (https://wolframsyndrome.wustl.edu) and all the participants in the Wolfram
- 302 syndrome International Registry and Clinical Study, Research Clinic, and Clinical Trials for their
- 303 time and efforts.

# 304 Data Availability Statement

- 305 The original contributions presented in the study are included in the article/Supplementary Material.
- 306 Further inquiries can be directed to the corresponding author.

- 308 [1] T.G. Barrett, S.E. Bundey, and A.F. Macleod, Neurodegeneration and diabetes: UK nationwide
   309 study of Wolfram (DIDMOAD) syndrome. The Lancet 346 (1995) 1458-1463.
- [2] M.L. de Heredia, R. Cleries, and V. Nunes, Genotypic classification of patients with Wolfram
   syndrome: insights into the natural history of the disease and correlation with phenotype.
   Genet Med 15 (2013) 497-506.
- [3] A. Samara, R. Rahn, O. Neyman, K.Y. Park, A. Samara, B. Marshall, J. Dougherty, and T.
   Hershey, Developmental hypomyelination in Wolfram syndrome: new insights from
   neuroimaging and gene expression analyses. Orphanet J Rare Dis 14 (2019) 279.
- [4] T. Doty, E.R. Foster, B. Marshall, S. Ranck, and T. Hershey, The effects of disease-related
   symptoms on daily function in Wolfram Syndrome. Transl Sci Rare Dis 2 (2017) 89-100.
- [5] F.C. Fraser, and T. Gunn, Diabetes mellitus, diabetes insipidus, and optic atrophy. An autosomal
   recessive syndrome? J Med Genet 14 (1977) 190-3.
- [6] D. Takei, H. Ishihara, S. Yamaguchi, T. Yamada, A. Tamura, H. Katagiri, Y. Maruyama, and Y.
   Oka, WFS1 protein modulates the free Ca(2+) concentration in the endoplasmic reticulum.
   FEBS Lett 580 (2006) 5635-40.
- [7] Z.Q. Shen, Y.L. Huang, Y.C. Teng, T.W. Wang, C.H. Kao, C.H. Yeh, and T.F. Tsai, CISD2
   maintains cellular homeostasis. Biochim Biophys Acta Mol Cell Res 1868 (2021) 118954.
- [8] S. Amr, C. Heisey, M. Zhang, X.J. Xia, K.H. Shows, K. Ajlouni, A. Pandya, L.S. Satin, H. El Shanti, and R. Shiang, A homozygous mutation in a novel zinc-finger protein, ERIS, is
   responsible for Wolfram syndrome 2. Am J Hum Genet 81 (2007) 673-83.
- [9] E. De Franco, S.E. Flanagan, T. Yagi, D. Abreu, J. Mahadevan, M.B. Johnson, G. Jones, F.
  Acosta, M. Mulaudzi, N. Lek, V. Oh, O. Petz, R. Caswell, S. Ellard, F. Urano, and A.T.
  Hattersley, Dominant ER Stress-Inducing WFS1 Mutations Underlie a Genetic Syndrome of
  Neonatal/Infancy-Onset Diabetes, Congenital Sensorineural Deafness, and Congenital
  Cataracts. Diabetes 66 (2017) 2044-2053.
- [10] F. Khanim, J. Kirk, F. Latif, and T.G. Barrett, WFS1/wolframin mutations, Wolfram syndrome,
   and associated diseases. Human Mutation 17 (2001) 357-367.
- [11] S. Noel, N. Servel, A. Hatton, A. Golec, M. Rodrat, D.R.S. Ng, H. Li, I. Pranke, A. Hinzpeter,
  A. Edelman, D.N. Sheppard, and I. Sermet-Gaudelus, Correlating genotype with phenotype
  using CFTR-mediated whole-cell Cl– currents in human nasal epithelial cells. The Journal of
  Physiology 600 (2022) 1515-1531.
- [12] Y. Wang, J.A. Wrennall, Z. Cai, H. Li, and D.N. Sheppard, Understanding how cystic fibrosis
   mutations disrupt CFTR function: from single molecules to animal models. Int J Biochem
   Cell Biol 52 (2014) 47-57.
- [13] G. Veit, R.G. Avramescu, A.N. Chiang, S.A. Houck, Z. Cai, K.W. Peters, J.S. Hong, H.B.
  Pollard, W.B. Guggino, W.E. Balch, W.R. Skach, G.R. Cutting, R.A. Frizzell, D.N.
  Sheppard, D.M. Cyr, E.J. Sorscher, J.L. Brodsky, and G.L. Lukacs, From CFTR biology
  toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations.
  Mol Biol Cell 27 (2016) 424-33.
- [14] G.R. Cutting, Cystic fibrosis genetics: from molecular understanding to clinical application. Nat
   Rev Genet 16 (2015) 45-56.
- [15] M. Claustres, C. Thèze, M. des Georges, D. Baux, E. Girodon, T. Bienvenu, M.P. Audrezet, I.
   Dugueperoux, C. Férec, G. Lalau, A. Pagin, A. Kitzis, V. Thoreau, V. Gaston, E. Bieth, M.C.

- 351 Malinge, M.P. Reboul, P. Fergelot, L. Lemonnier, C. Mekki, P. Fanen, A. Bergougnoux, S. 352 Sasorith, C. Raynal, and C. Bareil, CFTR-France, a national relational patient database for 353 sharing genetic and phenotypic data associated with rare CFTR variants. Hum Mutat 38 354 (2017) 1297-1315. 355 [16] V. Bansal, B.O. Boehm, and A. Darvasi, Identification of a missense variant in the WFS1 gene 356 that causes a mild form of Wolfram syndrome and is associated with risk for type 2 diabetes 357 in Ashkenazi Jewish individuals. Diabetologia 61 (2018) 2180-2188. 358 [17] A. Wilf-Yarkoni, O. Shor, A. Fellner, M.A. Hellmann, E. Pras, H. Yonath, S. Shkedi-Rafid, L. 359 Basel-Salmon, L. Bazak, R. Eliahou, L. Greenbaum, H. Stiebel-Kalish, F. Benninger, and Y. 360 Goldberg, Mild Phenotype of Wolfram Syndrome Associated With a Common Pathogenic 361 Variant Is Predicted by a Structural Model of Wolframin. Neurol Genet 7 (2021) e578. 362 [18] K.H. Gan, H.J. Veeze, A.M. van den Ouweland, D.J. Halley, H. Scheffer, A. van der Hout, S.E. 363 Overbeek, J.C. de Jongste, W. Bakker, and H.G. Heijerman, A cystic fibrosis mutation 364 associated with mild lung disease. N Engl J Med 333 (1995) 95-9. 365 [19] A.S. Dhaunchak, D.R. Colman, and K.A. Nave, Misalignment of PLP/DM20 transmembrane 366 domains determines protein misfolding in Pelizaeus-Merzbacher disease. J Neurosci 31 367 (2011) 14961-71. 368 [20] B. Xu, C. Allard, A.I. Alvarez-Mercado, T. Fuselier, J.H. Kim, L.A. Coons, S.C. Hewitt, F. 369 Urano, K.S. Korach, E.R. Levin, P. Arvan, Z.E. Floyd, and F. Mauvais-Jarvis, Estrogens 370 Promote Misfolded Proinsulin Degradation to Protect Insulin Production and Delay Diabetes. 371 Cell reports 24 (2018) 181-196. 372 [21] D. Abreu, R. Asada, J.M.P. Revilla, Z. Lavagnino, K. Kries, D.W. Piston, and F. Urano, 373 Wolfram syndrome 1 gene regulates pathways maintaining beta-cell health and survival. 374 Laboratory investigation; a journal of technical methods and pathology 100 (2020) 849-862. 375 [22] C. Nguyen, E.R. Foster, A.R. Paciorkowski, A. Viehoever, C. Considine, A. Bondurant, B.A. 376 Marshall, and T. Hershey, Reliability and validity of the Wolfram Unified Rating Scale 377 (WURS). Orphanet J Rare Dis 7 (2012) 89. 378 [23] S.A. Eisenstein, R.S. Boodram, C.L. Sutphen, H.M. Lugar, B.A. Gordon, B.A. Marshall, F. 379 Urano, A.M. Fagan, and T. Hershey, Plasma Neurofilament Light Chain Levels Are Elevated 380 in Children and Young Adults With Wolfram Syndrome. Front Neurosci 16 (2022) 795317. 381 [24] D. Abreu, S.I. Stone, T.S. Pearson, R.C. Bucelli, A.N. Simpson, S. Hurst, C.M. Brown, K. 382 Kries, C. Onwumere, H. Gu, J. Hoekel, L. Tychsen, G.P. Van Stavern, N.H. White, B.A. 383 Marshall, T. Hershey, and F. Urano, A phase Ib/IIa clinical trial of dantrolene sodium in 384 patients with Wolfram syndrome. JCI Insight 6 (2021). [25] K.Matsunage, K. Tanabe, H. Inoue, S. Okuya, Y. Ohata, M. Akiyama, A.Toguchi, Y.Kora, N. 385 386 Okayama, Y. Yamada, Y.Wada, S. Amemiya, S. Sugihara, Y. Nakao, Y. Oka, Y. Tanizawa, 387 Wolfram Syndrome in the Japanese Population; Molecular Analysis of WFS1 Gene and 388 Characterization of Clinical Features. PLOS ONE (2014). 389

#### Age of Diagnosis by Clinical Manifestation All Patients with Onset Data





(A)

Age of Diagnosis in Patients with Two In-Frame Variants, Number of Transmembrane vs Non-transmembrane In-Frame Variants





Age of Diagnosis in Patients with One In-Frame Variant, Number of Transmembrane vs Non-transmembrane In-Frame Variants



It is made available under a CC-BY-NC-ND 4.0 International license.

# Wolfram syndrome and WFS1-related disorders

(A)

0



Number of inframe variants in WFS1 transmembrane domains

1

0

2

1

Number of inframe variants in

WFS1 transmembrane domains